Association of class II and III BRAF mutations with EGFR blockade therapy response and representation of molecularly distinct subgroups of BRAF mutations in MMR proficient CRC

Authors:

Ibrahim Halil Sahin, Joanne Xiu, Moh’d M. Khushman, Emily Palumbo, Benjamin Adam Weinberg, Sanjay Goel, Aatur Singhi, Phoenix D Bell, Emil Lou, Anup Kasi, Anthony F. Shields, Matthew James Oberley, George W. Sledge Jr., John Paul Shen, Anwaar Saeed, Mohammedtaki Tejani

Key Finding:

  • In a study of 18,575 MMR-proficient colorectal cancers, Class II and III BRAF mutants were more likely to be seen in younger patients with improved outcomes from EGFR blockade.
Download Publication